Quick Answer
Elicio Therapeutics, Inc. reported Shares Outstanding of 17.80 million shares for fiscal year 2025.
Elicio Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 17.80M | +61.4% |
| 2024 | 11.03M | +14.8% |
| 2023 | 9.60M | +14.5% |
| 2023 | 8.39M | +2518.6% |
| 2022 | 320,281 | -98.9% |
| 2021 | 29.96M | +95.6% |
| 2020 | 15.32M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 17.26M | +60.0% | +6.1% |
| June 30, 2025 | 16.26M | +58.5% | +1.8% |
| March 31, 2025 | 15.97M | +56.3% | +44.8% |
| December 31, 2024 | 11.03M | +14.8% | +2.3% |
| September 30, 2024 | 10.78M | +28.7% | +5.1% |
| June 30, 2024 | 10.26M | +22.6% | +0.4% |
| March 31, 2024 | 10.22M | -66.1% | +6.4% |
| December 31, 2023 | 9.60M | — | +14.6% |
- Elicio Therapeutics, Inc. showed an increase of +61.4% in Shares Outstanding compared to the prior fiscal year.
- Over the 2020–2025 period, Elicio Therapeutics, Inc.’s shares outstanding has grown by 16.2% (from 15.32 million shares to 17.80 million shares).
- The most recent figure is from Elicio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: